NCT01692197View on ClinicalTrials.gov

E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

June 7, 2017

Study Completion Date

June 7, 2017

Conditions
Leukemia
Interventions
DRUG

E7070

400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.

DRUG

Idarubicin

8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).

DRUG

Cytarabine

1.0 g/m2 by vein daily on Days 9 - 12 (age \<60 years) or Days 9 - 11 (age \> 60 years).

DRUG

Dexamethasone

10 mg by vein daily for 3 - 4 days with cytarabine.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

Eisai Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01692197 - E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes | Biotech Hunter | Biotech Hunter